Disease activity early in treatment as a predictor of future low disease activity in RA patients treated with iguratimod

Abstract

Iguratimod was effective in RA patients in clinical practice. Our results suggest that 12 weeks may be a sufficient period to judge the medium-term efficacy of iguratimod in patients treated with and without MTX.

Efficacy and safety of iguratimod in the treatment of rheumatic and autoimmune diseases: a meta-analysis and systematic review of 84 randomized controlled trials

“…After the primary screening, 104 records were obtained. According to the inclusion and exclusion criteria and the completeness of the literature information, 18 records were excluded from the second screening after reading the full text (GuifengLi, 2014;He et al, 2015;Okamura et al, 2015;Meng et al, 2016a;Lin, 2016;Yoshioka et al, 2016;Zhu et al, 2016;Wang, 2017;Wang et al, 2017; Luo Y. et al, 2018;Wang X. et al, 2018;Huang and Ma, 2018;Luo et al, 2019;Shang et al, 2019;Suto et al, 2019;Gu et al, 2020; ManXie, 2020;Xu et al, 2021), and 86 records [(GuifengLi, 2014;Lü et al, 2008;Tian and Tao, 2017;Qi et al, 2019; Hara et al, 2014; Ishiguro et al, 2013; Li L. et al, 2019;Hu, 2014;Xia et al, 2020;Xia et al, 2016;Lu, 2014;Zhao et al, 2016;Shi et al, 2015;Meng et al, 2015;Bi, 2019;Zhang, 2018;Li et al, 2016;Mo et al, 2018;Duan et al, 2015;Xiong and GengGuanghui, 2020;Shang, 2014;Mo and Ma, 2015;Tian et al, 2020; Xu B. et al, 2015; Xu LM. et al, 2017;Yan and Wang, 2018;Fan et al, 2020;Meng et al, 2016b;Wang L. et al, 2019;…”

The Effect and Safety of Iguratimod Combined With Methotrexate on Rheumatoid Arthritis: A Systematic Review and Meta-Analysis Based on a Randomized Controlled Trial

“…After carefully reading the full text and comparing the selection criteria, 33 RCTs were screened out and finally included ( Shi et al, 2015 ; Lu 2014 ; Duan et al, 2015 ; Xiong et al, 2020 ; Xu et al, 2015 ; Ding et al, 2019 ; Deng et al, 2017 ; Tian et al, 2020 ; Xie et al, 2018 ; Xu et al, 2017 ; Bi et al, 2019 ; Yan et al, 2018 ; Tian et al, 2017 ; Chen et al, 2018 ; Xiong et al, 2015; Mo et al, 2015 ; Fan et al, 2020 ; Zhao et al, 2018 ; Li et al, 2020 ; Li et al, 2019 ; Meng et al, 2017 ; Li et al, 2016 ; Xia et al, 2020 ; Meng et al, 2015 ; Mo et al, 2018 ; Meng et al, 2016 ; Wang et al, 2019 ; Qi et al, 2019 ; Ju et al, 2020 ; Zhao et al, 2016 ; Hara et al, 2014 ; Ishiguro et al, 2013 ; Xia et al, 2016 ) ( Figure 1 ). The main reason why 12 studies were excluded is that eight studies are not RCTs ( Yoshioka et al, 2016 ; Wang et al, 2017 ; Suto et al, 2019 ; Okamura et al, 2015a , b ; Wang 2017 ; Meng et al, 2016 ; Gu et al, 2020 ), and the other four studies are not comparing IGU + MTX with MTX ( Liu 2016 ; Xu et al, 2017 ; Lu and Liu 2018 ; Zhu 2019 ).…”

Beneficial effects of natural eggshell membrane (NEM) on multiple indices of arthritis in collagen-induced arthritic rats

“…In addition, MMP-3 is a highly relevant biomarker in the context of RA, although there are no currently available agents that specifically target MMP-3 activity. Several recent studies in patients with RA have reported that baseline elevated MMP-3 is predictive of radiographic progression [31], and that treatment of patients with RA with either methotrexate or iguratimod lowers MMP-3 [31,[70][71][72][73][74][75].…”